• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Vaginal estrogen use and chronic disease risk in the Nurses’ Health Study
Conclusions: Vaginal estrogen use was not associated with a higher risk of cardiovascular disease or cancer. Our findings lend support to the safety of vaginal estrogen use, a highly effective treatment for genitourinary syndrome of menopause.
Source: Menopause - June 1, 2019 Category: OBGYN Tags: Original Articles Source Type: research

439OA first in human, phase I trial of NP137, a first-in-class antibody targeting netrin-1, in patients with advanced refractory solid tumors
ConclusionsNP137 was well-tolerated, with mild to moderate IRR as the most frequent treatment-related AEs and showed encouraging signs of clinical activity. Updated data will be presented at the meeting.Clinical trial identificationNCT02977195.Legal entity responsible for the studyCentre L éon Bérard.FundingNetris Pharma.DisclosureP. Cassier: Honoraria (self), Research grant / Funding (self), Research grant / Funding (institution), Travel / Accommodation / Expenses: AstraZeneca; Research grant / Funding (institution), Travel / Accommodation / Expenses: BMS; Research grant / Funding (institution), Travel / Accommodation /...
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research

Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG study.
CONCLUSION: The combination of trametinib and GSK2141795 had high levels of toxicity in endometrial cancer at the previously RP2D but was tolerable at a reduced dose. Due to insufficient preliminary efficacy at a tolerable dose, the Phase II study was not initiated. PMID: 31623857 [PubMed - as supplied by publisher]
Source: Gynecologic Oncology - October 14, 2019 Category: Cancer & Oncology Authors: Westin SN, Sill MW, Coleman RL, Waggoner S, Moore KN, Mathews CA, Martin LP, Modesitt SC, Lee S, Ju Z, Mills GB, Schilder RJ, Fracasso PM, Birrer MJ, Aghajanian C Tags: Gynecol Oncol Source Type: research

Structural and thermodynamic analyses of interactions between death-associated protein kinase 1 and anthraquinones
Death-associated protein kinase 1 (DAPK1) is a serine/threonine protein kinase that regulates apoptosis and autophagy. DAPK1 is considered to be a therapeutic target for amyloid- β deposition, endometrial adenocarcinomas and acute ischemic stroke. Here, the potent inhibitory activity of the natural anthraquinone purpurin against DAPK1 phosphorylation is shown. Thermodynamic analysis revealed that while the binding affinity of purpurin is similar to that of CPR005231, which is a DAPK1 inhibitor with an imidazopyridazine moiety, the binding of purpurin was more enthalpically favorable. In addition, the inhibition potencies ...
Source: Acta Crystallographica Section D - April 14, 2020 Category: Biochemistry Authors: Yokoyama, T. Wijaya, P. Kosaka, Y. Mizuguchi, M. Tags: DAPK1 kinase inhibitor purpurin – purpurin complex enthalpic forces apoptosis autophagy research papers Source Type: research

WHRY funds studies on stroke, endometrial cancer, and addiction to opioids
Women ’s Health Research at Yale is expanding its work to “address the enduring and pressing medical conditions that continue to affect women’s lives.”
Source: Yale Science and Health News - May 21, 2020 Category: Universities & Medical Training Source Type: news

Randomized Trial Evaluation of Benefits and Risks of Menopausal Hormone Therapy Among Women Aged 50-59.
Abstract The health benefits and risks of menopausal hormone therapy among women aged 50-59 years are examined in the Women's Health Initiative randomized, placebo-controlled trials using long-term follow-up data and a parsimonious statistical model that leverages data from older participants to increase precision. These trials enrolled 27,347 healthy post-menopausal women aged 50-79 at 40 U.S. clinical centers during 1993-1998, including 10,739 post-hysterectomy participants in a trial of conjugated equine estrogens, and 16,608 participants with uterus in the trial of these estrogens plus medroxyprogesterone acet...
Source: Am J Epidemiol - October 7, 2020 Category: Epidemiology Authors: Prentice RL, Aragaki AK, Chlebowski RT, Rossouw JE, Anderson GL, Stefanick ML, Wactawski-Wende J, Kuller LH, Wallace R, Johnson KC, Shadyab AH, Gass M, Manson JAE Tags: Am J Epidemiol Source Type: research

Oral mucosal changes induced by adjuvant endocrine therapies in breast cancer patients: clinical aspects and proposal for management
AbstractAdjuvant systemic treatments in breast cancer are indicated to reduce the risk of relapse. Their systemic side effects have been well documented and include menopausal symptoms such as impaired libido and vaginal dryness, increased risk of endometrial cancer, stroke, musculoskeletal symptoms including arthralgia and myalgia, osteopenia and fractures, skin rashes, and hypercholesterolemia. However, few articles have focused on the oral mucosal reactions related to adjuvant endocrine therapies (AETs) which clearly differ from those reported with chemotherapies or other targeted therapies used for breast cancer. AETs ...
Source: Supportive Care in Cancer - November 2, 2020 Category: Cancer & Oncology Source Type: research

Causes and Consequences of Polycystic Ovary Syndrome: Insights from Mendelian Randomization
CONCLUSIONS: The accumulation of genome-wide association studies in PCOS has enabled multiple MR analyses identifying factors that may cause PCOS or be caused by PCOS. This knowledge will be critical to future development of measures to prevent PCOS in girls at risk as well as prevent complications in those who have PCOS.PMID:34669940 | DOI:10.1210/clinem/dgab757
Source: Clinical Breast Cancer - October 20, 2021 Category: Cancer & Oncology Authors: Tiantian Zhu Mark O Goodarzi Source Type: research

Impact of Body Mass Index on Obesity-Related Cancer and Cardiovascular Disease Mortality; The Japan Collaborative Cohort Study
CONCLUSION: A BMI ≥ 25 kg/m2 is associated with an increased risk of obesity-related cancer in women and CVD in both sexes.PMID:34880165 | DOI:10.5551/jat.63143
Source: Journal of Atherosclerosis and Thrombosis - December 9, 2021 Category: Cardiology Authors: Masaaki Matsunaga Hiroshi Yatsuya Hiroyasu Iso Yuanying Li Kazumasa Yamagishi Naohito Tanabe Yasuhiko Wada Atsuhiko Ota Koji Tamakoshi Akiko Tamakoshi JACC Study Group Source Type: research

Pages: 1  2  3  4  5  6  7  8  9